Biohaven Ltd. Announces Pivotal Trials for Groundbreaking MoDE™ and TRAP™ Degraders Targeting Graves' Disease and IgA Nephropathy

Reuters

05-29

Biohaven Ltd. Announces Pivotal Trials for Groundbreaking MoDE™ and TRAP™ Degraders Targeting Graves' Disease and IgA Nephropathy

NEW HAVEN, Conn., May 28, 2025 - Biohaven Ltd. $(BHVN)$, a clinical-stage biopharmaceutical company, has announced plans to initiate pivotal trials for their drug candidates in the treatment of Graves' Disease and IgA nephropathy. The trials are set to begin in the second half of 2025 and the first half of 2026, respectively. During their recent R&D Day, Biohaven highlighted the success of their MoDE™ and TRAP™ degraders, specifically BHV-1300 and BHV-1400, which have shown significant selectivity and efficacy in early studies. BHV-1400, designed for IgA nephropathy, has achieved over 80% sustained reductions in galactose-deficient IgA1 levels, demonstrating potential as a first-in-class treatment. The drug was well-tolerated in Phase 1 trials, with most adverse events reported as mild and self-resolving. Biohaven's focus remains on advancing precision therapies for immune-mediated diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE97891) on May 28, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2539405200"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2539405200\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2539405200?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-29 03:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2539405200","market":"nz","top_or_hot":-1,"title":"Biohaven Ltd. Announces Pivotal Trials for Groundbreaking MoDE™ and TRAP™ Degraders Targeting Graves' Disease and IgA Nephropathy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Biohaven Ltd. Announces Pivotal Trials for Groundbreaking MoDE™ and TRAP™ Degraders Targeting Graves' Disease and IgA Nephropathy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NEW HAVEN, Conn., May 28, 2025 - Biohaven Ltd. <a href=\"https://laohu8.com/S/BHVN\">$(BHVN)$</a>, a clinical-stage biopharmaceutical company, has announced plans to initiate pivotal trials for their drug candidates in the treatment of Graves' Disease and IgA nephropathy. The trials are set to begin in the second half of 2025 and the first half of 2026, respectively. During their recent R&amp;D Day, Biohaven highlighted the success of their MoDE™ and TRAP™ degraders, specifically BHV-1300 and BHV-1400, which have shown significant selectivity and efficacy in early studies. BHV-1400, designed for IgA nephropathy, has achieved over 80% sustained reductions in galactose-deficient IgA1 levels, demonstrating potential as a first-in-class treatment. The drug was well-tolerated in Phase 1 trials, with most adverse events reported as mild and self-resolving. Biohaven's focus remains on advancing precision therapies for immune-mediated diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE97891) on May 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven Ltd. Announces Pivotal Trials for Groundbreaking MoDE™ and TRAP™ Degraders Targeting Graves' Disease and IgA Nephropathy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven Ltd. Announces Pivotal Trials for Groundbreaking MoDE™ and TRAP™ Degraders Targeting Graves' Disease and IgA Nephropathy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-29 03:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Biohaven Ltd. Announces Pivotal Trials for Groundbreaking MoDE™ and TRAP™ Degraders Targeting Graves' Disease and IgA Nephropathy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NEW HAVEN, Conn., May 28, 2025 - Biohaven Ltd. <a href=\"https://laohu8.com/S/BHVN\">$(BHVN)$</a>, a clinical-stage biopharmaceutical company, has announced plans to initiate pivotal trials for their drug candidates in the treatment of Graves' Disease and IgA nephropathy. The trials are set to begin in the second half of 2025 and the first half of 2026, respectively. During their recent R&amp;D Day, Biohaven highlighted the success of their MoDE™ and TRAP™ degraders, specifically BHV-1300 and BHV-1400, which have shown significant selectivity and efficacy in early studies. BHV-1400, designed for IgA nephropathy, has achieved over 80% sustained reductions in galactose-deficient IgA1 levels, demonstrating potential as a first-in-class treatment. The drug was well-tolerated in Phase 1 trials, with most adverse events reported as mild and self-resolving. Biohaven's focus remains on advancing precision therapies for immune-mediated diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE97891) on May 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL9rQ4vT:1","article_id":"2539405200","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2539405200","pubTimestamp":1748458826,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biohaven Ltd. Announces Pivotal Trials for Groundbreaking MoDE and TRAP Degraders Targeting Graves' Disease and IgA Nephropathy. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire  on May 28, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Biohaven Ltd.宣布针对格雷夫斯病和IgA肾病的突破性模式™和陷阱™降解剂的关键试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BHVN":0.9},"content_text":"Biohaven Ltd. Announces Pivotal Trials for Groundbreaking MoDE™ and TRAP™ Degraders Targeting Graves' Disease and IgA Nephropathy\n    \n\n        NEW HAVEN, Conn., May 28, 2025 - Biohaven Ltd. $(BHVN)$, a clinical-stage biopharmaceutical company, has announced plans to initiate pivotal trials for their drug candidates in the treatment of Graves' Disease and IgA nephropathy. The trials are set to begin in the second half of 2025 and the first half of 2026, respectively. During their recent R&D Day, Biohaven highlighted the success of their MoDE™ and TRAP™ degraders, specifically BHV-1300 and BHV-1400, which have shown significant selectivity and efficacy in early studies. BHV-1400, designed for IgA nephropathy, has achieved over 80% sustained reductions in galactose-deficient IgA1 levels, demonstrating potential as a first-in-class treatment. The drug was well-tolerated in Phase 1 trials, with most adverse events reported as mild and self-resolving. Biohaven's focus remains on advancing precision therapies for immune-mediated diseases.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE97891) on May 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}